RBC Capital analyst Brian Abrahams maintained a Buy rating on NeuBase Therapeutics (NBSE – Research Report) on December 24 and set a price target of $15.00. The company's shares closed last Tuesday at $2.74, close to its 52-week low of $2.52. According to TipRanks.com, Abrahams is a 3-star analyst with an average return of 1.3% and a 48.1% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, Karyopharm Therapeutics, and Enanta Pharmaceuticals. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for NeuBase Therapeutics. See the top stocks recommended by analysts >> NeuBase Therapeutics' market cap is currently $94.
https://www.tipranks.com/news/blurbs/rbc-capital-thinks-neubase-therapeutics-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral
NeuBase Therapeutics (NASDAQ:NBSE)
Historical Stock Chart
From Apr 2022 to May 2022 Click Here for more NeuBase Therapeutics Charts.
NeuBase Therapeutics (NASDAQ:NBSE)
Historical Stock Chart
From May 2021 to May 2022 Click Here for more NeuBase Therapeutics Charts.